Literature DB >> 10482989

Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation.

M Eder1, K Battmer, S Kafert, A Stucki, A Ganser, B Hertenstein.   

Abstract

To analyze the value of real time RT-PCR for monitoring of bcr-abl expression in CML patients after allogeneic or autologous stem cell transplantation (SCT), we generated pairs of PCR-primers and TaqMan probes specific for either the b2a2- or the b3a2-variant of bcr-abl. Either variant could be detected specifically from cDNA from a single K562 (b3a2) and BV173 (b2a2) cell with the respective TaqMan probe. Bcr-abl expression was normalized by comparison with GAPDH expression, and samples were quantitated using standard cDNA dilutions from K562 or BV173 cells. In a retrospective analysis 13 patients with CML after allogeneic (n = 10) or autologous (n = 3) SCT including patients with relapsed or persistent CML were analyzed by both real-time and conventional nested RT-PCR. In addition chimerism was monitored by FISH analysis of sex chromosomes in three patients with relapsed disease. The bcr-abl/GAPDH ratio dropped at least 1000-fold in all seven patients evaluable prior to and after allogeneic SCT as estimated by real-time RT-PCR, and conventional RT-PCR became negative in 6/7 patients. In five patients with relapsed or persistent disease after allogeneic SCT the bcr-abl/GAPDH ratio eventually increased again, and real-time RT-PCR was as sensitive as conventional RT-PCR for detection of bcr-abl. Donor lymphocyte infusions (DLI) were given to all five patients, and the bcr-abl/GAPDH ratio dropped to undetectable levels in two patients both remaining in continuing molecular remission. In contrast, in three other patients the bcr-abl/GAPDH ratio decreased only or did not change significantly after DLI. In three patients undergoing autologous SCT the bcr-abl/GAPDH ratio dropped only 1.1 to 30-fold, and the patients were tested positive with real-time RT-PCR at all time points. These data demonstrate that real-time RT-PCR is valuable to quantitate bcr-abl expression in CML patients after transplantation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482989     DOI: 10.1038/sj.leu.2401489

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

Review 1.  Clinical applications of BCR-ABL molecular testing in acute leukemia.

Authors:  Amgad L Nashed; Kathleen W Rao; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Quantitative intra-individual monitoring of BCR-ABL transcript levels in archival bone marrow trephines of patients with chronic myeloid leukemia.

Authors:  Oliver Bock; Ulrich Lehmann; Hans Kreipe
Journal:  J Mol Diagn       Date:  2003-02       Impact factor: 5.568

3.  Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.

Authors:  You Kyoung Lee; Dong Wha Lee; Yoo Li Kim; Seok Lee; Chang Ki Min; Yoo-Jin Kim; Il-Hoan Oh; Tai-Gyu Kim; Chun Choo Kim; Dong-Wook Kim
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Trisomy 22 as the sole karyotypic abnormality in myelodysplastic syndrome.

Authors:  Tohru Takahashi; Sayaka Harada; Mariko Oki; Mitsuru Yoshimoto; Masayuki Tsujisaki
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

5.  Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses.

Authors:  Rupali Das; Richard Komorowski; Martin J Hessner; Hariharan Subramanian; Claudia S Huettner; Daniel Cua; William R Drobyski
Journal:  Blood       Date:  2010-04-09       Impact factor: 22.113

6.  Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.

Authors:  Y Lynn Wang; Joong Won Lee; Ethel Cesarman; David K Jin; Balazs Csernus
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

7.  Usefulness of quantitative assessment of JunB gene expression as a marker for monitoring chronic myeloid leukemia patients undergoing imatinib therapy.

Authors:  Yi-Chang Liu; Hui-Hua Hsiao; Jan-Gowth Chang; Ming-Yu Yang; Ta-Chih Liu; Chao-Song Chang; Shih-Bin Tseng; Huei-Jen Tsai; Sheng-Fung Lin
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

8.  Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Authors:  Mats Hardling; Yuan Wei; Lars Palmqvist; Birgitta Swolin; Dick Stockelberg; Bengt Gustavsson; Kerstin Ekeland-Sjöberg; Hans Wadenvik; Anne Ricksten
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.